Cargando…

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin, Hu, Changwei, Xie, Xiaoxiao, Qi, Linzhi, Li, Chuanzhou, Li, Shangze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059020/
https://www.ncbi.nlm.nih.gov/pubmed/36992198
http://dx.doi.org/10.3390/vaccines11030614
_version_ 1785016775064158208
author Zhang, Jin
Hu, Changwei
Xie, Xiaoxiao
Qi, Linzhi
Li, Chuanzhou
Li, Shangze
author_facet Zhang, Jin
Hu, Changwei
Xie, Xiaoxiao
Qi, Linzhi
Li, Chuanzhou
Li, Shangze
author_sort Zhang, Jin
collection PubMed
description Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV-HCC); meanwhile, in the advanced stage, chemoradiotherapy and drug-targeted therapy are regularly considered, but with limited efficacy. Recently, immunotherapies, such as tumor vaccine therapy, adoptive cell transfer therapy, and immune checkpoint inhibitor therapy, have demonstrated promising efficacy in cancer treatment. In particular, immune checkpoint inhibitors can successfully prevent tumors from achieving immune escape and promote an anti-tumor response, thereby boosting the therapeutic effect in HBV-HCC. However, the advantages of immune checkpoint inhibitors in the treatment of HBV-HCC remain to be exploited. Here, we describe the basic characteristics and development of HBV-HCC and introduce current treatment strategies for HBV-HCC. Of note, we review the principles of immune checkpoint molecules, such as programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in HBV-HCC, as well as related inhibitors being considered in the clinic. We also discuss the benefits of immune checkpoint inhibitors in the treatment of HBV-HCC and the efficacy of those inhibitors in HCC with various etiologies, aiming to provide insights into the use of immune checkpoint inhibitors for the treatment of HBV-HCC.
format Online
Article
Text
id pubmed-10059020
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100590202023-03-30 Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy Zhang, Jin Hu, Changwei Xie, Xiaoxiao Qi, Linzhi Li, Chuanzhou Li, Shangze Vaccines (Basel) Review Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV-HCC); meanwhile, in the advanced stage, chemoradiotherapy and drug-targeted therapy are regularly considered, but with limited efficacy. Recently, immunotherapies, such as tumor vaccine therapy, adoptive cell transfer therapy, and immune checkpoint inhibitor therapy, have demonstrated promising efficacy in cancer treatment. In particular, immune checkpoint inhibitors can successfully prevent tumors from achieving immune escape and promote an anti-tumor response, thereby boosting the therapeutic effect in HBV-HCC. However, the advantages of immune checkpoint inhibitors in the treatment of HBV-HCC remain to be exploited. Here, we describe the basic characteristics and development of HBV-HCC and introduce current treatment strategies for HBV-HCC. Of note, we review the principles of immune checkpoint molecules, such as programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in HBV-HCC, as well as related inhibitors being considered in the clinic. We also discuss the benefits of immune checkpoint inhibitors in the treatment of HBV-HCC and the efficacy of those inhibitors in HCC with various etiologies, aiming to provide insights into the use of immune checkpoint inhibitors for the treatment of HBV-HCC. MDPI 2023-03-08 /pmc/articles/PMC10059020/ /pubmed/36992198 http://dx.doi.org/10.3390/vaccines11030614 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhang, Jin
Hu, Changwei
Xie, Xiaoxiao
Qi, Linzhi
Li, Chuanzhou
Li, Shangze
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title_full Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title_fullStr Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title_full_unstemmed Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title_short Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
title_sort immune checkpoint inhibitors in hbv-caused hepatocellular carcinoma therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059020/
https://www.ncbi.nlm.nih.gov/pubmed/36992198
http://dx.doi.org/10.3390/vaccines11030614
work_keys_str_mv AT zhangjin immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy
AT huchangwei immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy
AT xiexiaoxiao immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy
AT qilinzhi immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy
AT lichuanzhou immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy
AT lishangze immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy